Statement of Principles concerning smallpox (Reasonable Hypothesis) (No. 5 of 2026)

The instrument is structured around a narrow set of concepts and thresholds. The core legal concept is the "reasonable hypothesis" standard for linking a specified injury or disease to relevant service. The RMA sets out which factors, and the circumstances in which they must exist, such that a reasonable hypothesis is raised (s9; s10). The instrument does not define the broader meaning of "reasonable hypothesis" beyond stating the factors that must exist to raise it; the focus is the prescriptive list in s9.

Key definitional points:

• Smallpox is defined, for these purposes, as a clinical illness caused by variola virus infection and confirmed by laboratory testing, including variola major and variola minor (s7(2)). The instrument clarifies that while ICD‑10‑AM code B03 corresponds to smallpox, the statutory meaning is that in subsection (2) (s7(3) and note).
• Death from smallpox extends to death from a terminal event or condition that was contributed to by the person's smallpox (s7(4); Schedule 1 definition of terminal event). The Schedule lists proximate or ultimate causes of death that qualify, with examples (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function).
• Relevant service is defined in the Schedule and encompasses the VEA categories of operational, peacekeeping, hazardous and British nuclear test defence service, and the MRCA categories of warlike and non‑warlike service (Schedule 1).

The factor list in section 9 is the operational core. It requires at least one of the following to exist to raise the reasonable hypothesis:

• Direct or indirect exposure to variola virus within four weeks prior to clinical onset. The listed exposure modes include close contact with an infected person, direct contact with infected body fluids or tissue, direct contact with a laboratory strain of variola, handling contaminated clothing or bedding or objects, skin penetration by contaminated instruments, or inhaling droplet nuclei or aerosols of variola virus (s9(1) and its subparagraphs). The four week timing window is explicit.
• Inability to access appropriate smallpox vaccination in accordance with contemporary medical standards of the time, within the two years immediately preceding clinical onset (s9(2)).
• Pregnancy within the six weeks immediately preceding clinical onset of haemorrhagic type smallpox or death from smallpox (s9(3)). The instrument notes the clinical severity of haemorrhagic type smallpox in the notes accompanying s9(3).
• Having a substantially compromised immune system at the time of clinical worsening, with specified conditions and thresholds: chronic renal failure indicated by GFR less than 15 mL/min/1.73 m2 for at least three months, or undergoing chronic dialysis; haematological or solid organ malignancy; HIV infection; severe malnutrition defined by BMI ≤18.5 kg/m2; solid organ, stem cell or bone marrow transplantation; or taking specified systemic immunosuppressive medications (s9(4) and subparagraphs).
• Inability to obtain appropriate clinical management for smallpox before clinical worsening (s9(6)).

Notable conceptual constraints and interactions within the instrument:

• Timing thresholds are explicit and vary by factor: four weeks for exposure, two years for vaccination access, six weeks for pregnancy, three months for chronic renal failure GFR threshold, BMI cut‑off for malnutrition (s9 and accompanying note).
• The clinical worsening wording operates only to assess material contribution or aggravation where the smallpox was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s10(2)). Thus, the instrument distinguishes between causation arising out of service and aggravation during service.
• Section 11 provides a cross‑reference mechanism: if a factor in s9 refers to an injury or disease covered by another Statement of Principles determined under s196B(2) of the VEA, then the factors in that other Statement of Principles apply in accordance with its terms (s11). This creates an inter‑instrument dependency where the assessment of a s9 factor may require consulting a different Statement of Principles.

These elements together form an evidentiary checklist that decision‑makers and claimants must navigate. The RMA presents the list as the medical‑scientific basis for raising a reasonable hypothesis linking smallpox or death from smallpox to relevant service (s8). The instrument is, therefore, an administrative medical‑evidentiary standard rather than a statutory grant of benefits or a schedule of penalties.

The instrument targets claims made under the VEA and MRCA frameworks. It expressly applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). The RMA’s statement of view in s8 identifies the relevant populations to whom that view pertains: veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA (s8). The Schedule defines "relevant service" and lists the categories of service that bring a person within the scope of the instrument: operational, peacekeeping, hazardous, British nuclear test defence under the VEA; warlike and non‑warlike service under the MRCA (Schedule 1).

Concrete affected actors and their practical roles under the instrument:

• Claimants: individuals who lodge claims under the specified provisions of the VEA or MRCA and who assert that they have smallpox or died from smallpox, and who wish to establish a reasonable hypothesis that the disease was connected to relevant service (s5, s7, s9). To engage the instrument a claimant must have the kind of disease or death described by the instrument , laboratory‑confirmed variola infection or death from a terminal event contributed to by smallpox (s7(2), s7(4), Schedule 1).
• Decision‑makers and medical assessors operating under VEA/MRCA claim streams: the instrument creates a list of medical/clinical factors that must be considered to determine whether a reasonable hypothesis is raised. While the instrument does not expressly command a specific decision procedure, it prescribes the factors decision‑makers must treat as sufficient to raise the reasonable hypothesis if established (s9, s10, s11).
• Medical practitioners and laboratories: the definition of smallpox requires laboratory confirmation of variola virus infection (s7(2)). That makes laboratory results relevant evidence in claims governed by this instrument.
• Records custodians within Defence, health services, and other institutions: because many s9 factors are time‑bound and clinical (vaccination within two years, exposure within four weeks, GFR over a three month period, BMI at or below 18.5), documentary evidence held by health services, service medical records, immunisation records and laboratory reports will be the primary material used to apply the instrument (s9 and Schedule 1).
• Administrators applying multiple Statements of Principles: where a s9 factor refers to an injury or disease covered by another Statement of Principles, administrators must consult that other instrument and apply its terms (s11).

The instrument therefore affects the evidentiary burden and record collection activities of claimants and those who advise or make determinations on claims under the VEA and MRCA. It also affects how medical evidence is assessed, because it sets definitional and timing thresholds that determine whether a “reasonable hypothesis” is raised for the purposes of the statutory claim streams specified in s5.

The instrument itself is prescriptive about what factual and clinical factors must exist to raise a reasonable hypothesis linking smallpox or death from smallpox to relevant service. It does not create new statutory rights to payment, nor does it specify duties in the criminal or civil sense. Instead, its legal effect is to operate as the RMA’s authoritative statement for decision‑makers considering whether a reasonable hypothesis has been raised under the specified claim provisions of the VEA and the MRCA.

Key operational duties and entitlements implicit from the instrument are:

• Duty to meet the definitional threshold for smallpox: claimants must establish that the condition in issue is smallpox as defined in subsection 7(2), that is a clinical illness caused by variola virus confirmed by laboratory testing (s7(2)). If a claimed condition does not satisfy that definition, the instrument does not apply.
• Duty to establish at least one qualifying factor in section 9: the instrument requires that at least one of the enumerated factors exist before a reasonable hypothesis can be said to be raised. The factors are specific and time‑bounded,exposure within four weeks of onset, inability to access vaccination within two years prior to onset, pregnancy within six weeks prior to the onset of haemorrhagic type smallpox or death from smallpox, specified forms of immune compromise at the time of clinical worsening, or inability to obtain appropriate clinical management before clinical worsening (s9).
• Duty to relate the factor to relevant service: the instrument requires that any s9 factor relied on be related to the person’s relevant service as defined in the Schedule (s10(1)). This is a connectivity requirement: it is not enough that a factor exists in isolation; it must have a relationship to the person’s relevant service.
• Constraint on clinical worsening factors: where an s9 factor uses the clinical worsening formulation, that formulation applies only to material contribution to or aggravation of smallpox where the disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s10(2)). This confines the operation of aggravation to particular temporal relationships with relevant service.
• Right to have cross‑referenced factors from other Statements of Principles applied: where an s9 factor refers to an injury or disease covered by a separate Statement of Principles determined under s196B(2) of the VEA, that other instrument’s factors apply in accordance with its terms (s11). This is a right of inter‑instrument application that may expand or refine the evidentiary pathway for certain factors.

The instrument is silent on procedural mechanics such as burden of proof allocation or how the statutory decision maker must weigh competing evidence. It does, however, supply precise clinical and timing thresholds that will functionally define the evidence necessary to meet the RMA’s standard. For example, the requirement for laboratory confirmation of variola virus infection (s7(2)) and the explicit windows for exposure and vaccination access (s9(1), s9(2)) mean that documentary medical and laboratory evidence will be central to meeting the instrument’s criteria.

No enforcement duties, criminal sanctions or administrative penalties are specified in the text of the instrument. Its role is to set medical‑scientific criteria for raising a reasonable hypothesis in the relevant claim streams (s3, s5, s8).

The Statement of Principles is an administrative medical‑evidentiary instrument. The instrument contains no provisions imposing criminal sanctions, civil penalties, administrative fines or other enforcement measures. It does not create an offence or prescribe enforcement mechanisms in its text. Its statutory source is the Repatriation Medical Authority’s power under subsection 196B(2) of the Veterans' Entitlements Act 1986 to determine Statements of Principles. The instrument is directed at the medical and factual threshold for a reasonable hypothesis in claims under specified provisions of the VEA and MRCA (s3, s5, s8).

Practical enforcement‑adjacent effects, deriving from the instrument’s role in claim assessment, are:

• Evidentiary gatekeeping: by specifying definitional and temporal thresholds, the instrument functions as an evidentiary gate. Decision‑makers assessing whether a reasonable hypothesis is raised will use the s9 factors and s7 definition for smallpox as the RMA’s authoritative medical guidance. Where the required factors or definitional elements are not established, a decision maker may determine that the reasonable hypothesis threshold is not met. The instrument itself does not set the decision maker’s legal processes, but it sets the clinical facts that must be demonstrated to satisfy the RMA’s test (s7, s9, s10).
• Administrative reliance: administrators, medical assessors and decision‑makers operating under the VEA/MRCA claim processes are obliged, in practice, to account for the RMA’s Statement of Principles when applying the statutory tests referenced in s5. The instrument cross‑references other Statements of Principles where applicable, creating an enforcement network among RMA instruments (s11).
• No express procedural remedies or appeal routes contained in the instrument: the text does not specify dispute resolution, review mechanisms or penalties for non‑compliance with any specified duty beyond the operation of existing VEA and MRCA claim procedures. Any such procedural rights or penalties reside outside the instrument in the statutory frameworks to which it applies (s5).

In short, this instrument is a standards‑setting document. It prescribes the clinical and factual criteria that are to be used in raising a reasonable hypothesis for smallpox and related death for claim purposes. It does not itself enforce outcomes by penalties, but it will materially influence the acceptance or rejection of claims because it defines the clinical evidence and temporal windows relevant to the claim assessment process under the applicable statutory provisions (s7, s9, s10, s11).

The instrument is drafted to operate within the VEA and MRCA claim frameworks. It is made under subsection 196B(2) of the VEA (s3) and expressly applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). Consequently, its interaction with other laws is primarily as an interpretive and evidentiary input into decision‑making processes created by those statutes.

Explicit interactions set out in the instrument:

• VEA and MRCA: the Schedule defines "relevant service" by reference to categories within the VEA and MRCA (Schedule 1). The instrument’s factors must be related to relevant service (s10(1)), linking the medical findings to the statutory categories of service. The instrument therefore interacts with the statutory tests for causation and the operational definitions used in the VEA and MRCA claim streams.
• Other Statements of Principles determined under subsection 196B(2) of the VEA: section 11 provides a formal mechanism for cross‑application. If an s9 factor refers to an injury or disease that is itself the subject of another Statement of Principles, then the factors in that other Statement will apply according to its terms. This creates a structured interaction between different RMA instruments, ensuring consistency and deference to existing Statements of Principles where overlap occurs (s11).
• Classification systems: the instrument mentions ICD‑10‑AM coding. It notes that while smallpox attracts ICD‑10‑AM code B03, the meaning of smallpox for the instrument is the laboratory confirmation definition in subsection 7(2) (s7(3) and note). The instrument also specifies the edition and effective date of the ICD‑10‑AM referenced (Tenth Edition, effective date 1 July 2017). This makes clear that administrative classification systems may be informative but are subordinate to the instrument’s statutory definition.
• Medical thresholds and records regimes: the definitions and factor thresholds in the instrument will intersect with clinical record keeping obligations under other health and Defence record regimes. For example, the GFR threshold for chronic renal failure, BMI thresholds for malnutrition, transplant status, HIV infection, cancer diagnosis and medication lists are clinical elements that are documented under other regulatory regimes. The instrument imports those clinical thresholds into the VEA/MRCA claim context (s9(4) and subparagraphs).
• Repeal of prior RMA instrument: the instrument expressly repeals the earlier smallpox Statement of Principles (No. 89 of 2016) (s4). This is a direct interaction by replacement; any application of the RMA’s smallpox principles after commencement will be governed by the 2026 instrument rather than the 2016 instrument.

Areas where the instrument is silent, but relevant intersections may exist in practice:

• The instrument does not set procedural rules for how to prove the factors before adjudicators. Those procedural mechanisms and any appeal or review processes are governed by the VEA and MRCA and associated procedural law rather than by the instrument itself (s5).
• The instrument does not explicitly address conflicts between clinical evidence and service records beyond the requirement that the factor be related to relevant service (s10(1)). Implementing agencies will therefore need to reconcile evidence under the respective statutory processes.

The instrument is designed to be read and applied in conjunction with the VEA and MRCA statutory frameworks and with other Statements of Principles as necessary (s3, s5, s11). It sets clinical and temporal thresholds that become inputs into statutory decision making under those laws.

The instrument contains a limited, explicit amendment history in the form of repeal and replacement. It was determined by the Repatriation Medical Authority and dated 19 December 2025 (cover page and signature block). It commences on 19 January 2026 (s2). Section 4 expressly repeals the Statement of Principles concerning smallpox (Reasonable Hypothesis) (No. 89 of 2016) (Federal Register of Legislation No. F2016L01669) made under subsection 196B(2) of the VEA. The 2016 instrument is therefore superseded as from the commencement date of this instrument (s4).

No other amendments are recorded within this instrument. There are no savings, transitional provisions, or qualifications included in the text about how claims already in process at the time of repeal are to be treated. The instrument simply repeals the 2016 Statement of Principles and sets a commencement date for the 2026 instrument (s2, s4).

Because the instrument functions as an RMA determination under s196B(2) of the VEA, any future changes to how smallpox is treated in claims would be effected by later RMA determinations or by legislative amendment to the VEA or MRCA. The instrument itself does not contain provisions for future amendment, sunset clauses, or review mechanisms. It does, however, explicitly provide that where factors in s9 refer to conditions covered by other Statements of Principles, those other instruments apply as in force from time to time (s11). That language anticipates that other Statements of Principles may themselves be amended, and that such amendments will flow through to the application of cross‑referenced factors.

In summary, the concrete amendment history recorded by the instrument is:

• 2016 instrument on smallpox (No. 89 of 2016) existed and is expressly repealed by this 2026 instrument (s4).
• The 2026 instrument is dated 19 December 2025 and commences 19 January 2026 (cover and s2).

No further historical changes or prior versions beyond the 2016 instrument are referenced in the text.

The instrument itself contains no reference to any litigation, judicial decisions, or appellate authority. It does not name any cases and does not summarise or cite judicial interpretations. The only legal instruments named within the text are the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, and the prior RMA Statement of Principles from 2016 which is repealed (s3, s4, Schedule 1).

Because the Statement of Principles is an administrative medical standard determined under subsection 196B(2) of the VEA, relevant litigation, if any, would occur in the context of VEA/MRCA decisions where claimants challenge statutory decisions and evidence‑based inferences about causation or aggravation. The instrument, however, does not record any such litigation history or existing case law. It contains no guidance on judicial deference, standard of review, or how courts have treated RMA Statements of Principles. The document is silent on:

• Any past disputes over the 2016 Statement of Principles or other RMA determinations concerning smallpox;
• Any reported judicial or tribunal decisions construing the RMA’s Statements of Principles or the application of the reasonable hypothesis test for smallpox specifically;
• Any precedent that would guide the interpretation of the clinical thresholds in the instrument.

For practitioners needing to advise on litigation risk or appellate prospects, this instrument provides the RMA’s current medical‑scientific criteria to be applied at the administrative decision stage. Any litigation history relevant to these criteria must be identified outside this instrument because the instrument itself contains no litigation notes, citations or discussion.

The text contains several specific drafting choices and precise thresholds that can generate evidence and application pitfalls for claimants, advisers and decision‑makers. The following are concrete items to watch for, directly tied to the instrument’s wording.

1. Laboratory confirmation requirement for smallpox

• The definition of smallpox requires laboratory confirmation of infection with variola virus (s7(2)). A clinical diagnosis which lacks laboratory confirmation will not meet the instrument’s definition of smallpox for these claims. Practitioners should not substitute ICD‑10‑AM coding alone for laboratory confirmation; the instrument notes that while smallpox attracts ICD‑10‑AM code B03, the statutory meaning is the laboratory‑confirmed variola infection in s7(2) (s7(3) and note).

2. Short exposure window

• Exposure must occur within the four weeks immediately preceding clinical onset for the exposure factor to count (s9(1)). Claims that rely on exposures outside that four week window will not satisfy the exposure factor as drafted. Proof of timing therefore matters.

3. Vaccination access is time‑bounded and qualified

• Inability to access appropriate smallpox vaccination must be within the two years immediately preceding clinical onset and must be measured against "contemporary medical standards of the time" (s9(2)). The temporal phrase "contemporary medical standards" introduces a standards‑of‑care question requiring historical clinical evidence about what vaccination was appropriate at the time claimed. That can be evidentially challenging.

4. Pregnancy factor is narrow

• The pregnancy factor applies only if pregnancy occurred within the six weeks immediately preceding clinical onset of haemorrhagic type smallpox or death from smallpox (s9(3)). It is not a general pregnancy aggravation factor. The instrument’s note emphasises that haemorrhagic type smallpox typically involves severe clinical features, signalling that the pregnancy factor is limited in scope.

5. Immune compromise definitions contain precise numeric thresholds and exclusions

• Chronic renal failure is defined by a GFR threshold less than 15 mL/min/1.73 m2 for at least three months or ongoing chronic dialysis (s9(4)(a) and subparagraphs). Severe malnutrition is defined by BMI ≤18.5 kg/m2 (s9(4)(d) and note). Corticosteroid immunosuppression excludes inhaled or topical corticosteroids; only systemic corticosteroids are captured (s9(4)(f)(i)). These precise thresholds create discrete evidentiary hurdles.

6. Clinical worsening limitation

• The instrument states that the clinical worsening aspects of certain factors apply only to material contribution to, or aggravation of, smallpox where the disease was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s10(2)). That means clinical worsening cannot be used to connect conditions that arose out of service; it only applies in the stated temporal relationship. Practitioners must carefully categorise whether the disease arose out of service or merely preceded/during service for the clinical worsening formulation to be usable.

7. Cross‑instrument application

• Where a factor in s9 refers to an injury or disease that is itself the subject of another RMA Statement of Principles, the other Statement’s factors apply as in force from time to time (s11). That improves coherence but introduces procedural complexity. Claimants and decision‑makers must identify and consult other relevant Statements of Principles and reconcile their terms.

8. Repeal and commencement timing

• The 2016 instrument is repealed (s4) and the 2026 instrument commences on a specified date (s2). For claims straddling the repeal/commencement, the instrument is silent about transitional treatment. Practitioners should therefore verify which instrument governs any given claim based on the relevant dates.

9. No procedural detail in the instrument

• The instrument sets medical criteria but contains no guidance on how to adjudicate disputes about conflicting evidence, allocation of proof, or appeal pathways. Those matters are governed by the VEA/MRCA frameworks rather than by this Statement of Principles (s5). Practitioners must therefore reconcile the RMA’s medical standards with the procedural law that sits outside the instrument.

10. Terminal event inclusions but not exclusive list

• The Schedule lists examples of terminal events that count as death from smallpox if contributed to by the smallpox (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) (Schedule 1). The text clarifies that “terminal event” means the proximate or ultimate cause of death and includes the listed items; the list is illustrative rather than exhaustive. Adjudicators will need to assess whether another terminal event not listed was contributed to by smallpox.

These are not speculative risks. Each emerges from the instrument’s precise phrasing and thresholds and will determine what documentary and clinical evidence is necessary to satisfy the RMA’s reasonable hypothesis standard for smallpox‑related claims.

For claimants, advisers and decision‑makers, compliance with and application of this instrument requires a focused approach to evidence collection, chronology, and cross‑referencing with other Statements of Principles where necessary. Below are concrete steps and document types, grounded in the instrument’s text, to assemble and present a compliant evidentiary case.

1. Establish the kind of disease or death

• Obtain laboratory reports confirming infection with variola virus. The definition of smallpox requires laboratory confirmation (s7(2)). Where death is claimed, obtain the death certificate, terminal event documentation, and any medical evidence demonstrating that the terminal event was contributed to by smallpox (s7(4); Schedule 1).

2. Identify and document at least one s9 factor

• Exposure within four weeks: Collect contemporaneous service records, duty logs, deployment rosters, witness statements and clinical notes that identify close contact with a person who had smallpox, direct contact with infected body fluids or tissue, contact with a laboratory strain of variola, handling of contaminated clothing or objects, instrument‑associated skin penetration, or inhalation exposure. Ensure timing shows exposure occurred within the four weeks immediately preceding clinical onset (s9(1)).
• Inability to access vaccination within two years: Produce immunisation records, attempts to access vaccination, denial letters, supply shortage documentation or correspondence demonstrating inability to obtain "appropriate smallpox vaccination in accordance with contemporary medical standards of the time" within the two years immediately preceding onset (s9(2)). Because the instrument requires reference to contemporary medical standards, include contemporaneous clinical guidance or policy documents from the relevant period to demonstrate the applicable standard.
• Pregnancy within six weeks preceding haemorrhagic type presentation or death: Where relevant, collect antenatal and obstetric records showing pregnancy dates and documentation establishing haemorrhagic type presentation or death from smallpox (s9(3) and accompanying note).
• Immunocompromise at time of clinical worsening: Collect medical records demonstrating chronic renal failure with GFR measurements over time (showing GFR <15 mL/min/1.73 m2 for at least three months), records of chronic dialysis, biopsy or oncological records confirming haematological or solid organ malignancy, HIV diagnosis records, nutrition records establishing BMI ≤18.5 kg/m2, transplant operation records, or medication lists confirming systemic immunosuppressive medications in the classes listed (systemic corticosteroids, transplant rejection drugs, tumour necrosis factor‑α inhibitors, chemotherapeutic agents for cancer) (s9(4) and subparagraphs). Note that inhaled or topical corticosteroids are excluded from the corticosteroid category.
• Inability to obtain appropriate clinical management before clinical worsening: Assemble correspondence, referral records, hospital admission records, or health system denial/triage documentation demonstrating that appropriate clinical management for smallpox was not available prior to clinical worsening (s9(6)).

3. Demonstrate relationship to relevant service

• For any s9 factor relied upon, gather service records and other evidence to show how the factor relates to the person’s relevant service as defined in the Schedule: operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA (s10(1); Schedule 1). This may include postings, unit assignments, medical encounters while in service, and contemporaneous duty descriptions.

4. Address clinical worsening and temporal constraints

• If relying on clinical worsening formulations, ensure that the smallpox was suffered or contracted before or during, but did not arise out of, the person’s relevant service (s10(2)). Document the timeline of disease onset in relation to service periods to show the appropriate temporal relationship.

5. Cross‑reference other Statements of Principles where necessary

• If an s9 factor refers to a condition covered by another Statement of Principles, identify that other Statement and collect the evidence that it requires. Section 11 mandates that the other Statement’s factors apply as in force from time to time (s11). Practically, this may require consulting the RMA’s register of Statements of Principles and applying them in tandem.

6. Present laboratory and coding evidence correctly

• Because the instrument prioritises laboratory confirmation over ICD‑10‑AM coding, include laboratory confirmation and do not rely solely on an ICD‑10‑AM code B03 entry to establish smallpox for the purposes of the instrument (s7(2), s7(3) and note). If ICD coding is used in administrative records, also include the laboratory evidence that satisfies the statutory definition.

7. Prepare to address evidentiary gaps around "contemporary medical standards"

• Where inability to access vaccination is claimed, assemble contemporaneous public health guidance, policy documents, Defence vaccination policies, procurement records or clinical advisory statements showing what vaccination was considered “appropriate” at the relevant time. The instrument’s reference to "contemporary medical standards of the time" (s9(2)) introduces a standards‑of‑care question that will require contemporaneous documentary proof.

8. Record numeric clinical thresholds carefully

• Ensure GFR measurements, BMI calculations and medication details are clearly documented. The instrument specifies numeric thresholds (GFR <15 mL/min/1.73 m2 for at least three months; BMI ≤18.5 kg/m2) and medication classes (s9(4) and note). Present serial measurements where needed to demonstrate sustained thresholds.

9. For administrators and decision‑makers

• Use the instrument as the RMA’s medical standard when assessing whether a reasonable hypothesis is raised under the claim provisions specified in s5. Identify any cross‑referenced Statements of Principles early and reconcile their requirements. If an s9 factor is contested, request the specific documentary evidence required by the factor (laboratory reports, service records, vaccination access documentation, GFR/BMI/medication records, transplant records). Record the temporal connections between onset and service carefully in the decision file because s10(2) constrains clinical worsening applicability.

10. Check commencement and repeal dates for transitional cases

• For claims whose events fall near the repeal and commencement dates, confirm which Statement of Principles is applicable. The 2016 instrument is repealed and this 2026 instrument commences on the date specified (s2, s4). The instrument does not include transitional rules; practitioners should determine which Statement governs based on the instrument’s commencement date and the timing of the claim.

Following the above steps, with documentary evidence tied to the precise statutory thresholds in s7, s9 and s10, aligns the factual record with the RMA’s medical criteria and enables decision‑makers to assess whether a reasonable hypothesis has been raised for the purposes of claims under the VEA and MRCA (s5, s8).